How do you tell if your pipeline coverage is over-stuffed with deals that won't close versus genuinely fat?

The Real Test: Pipeline Health vs. Pipeline Fiction

Fat pipelines feel good until forecast misses start stacking. The difference between inflated numbers and legit coverage comes down to deal velocity and win-rate conversion. If your ACV × win rate × close rate doesn't match historical actuals, you're carrying deadweight.

What Separates Fat Pipeline from Pipe Dream

The Math First

Your true coverage ratio should be: *(Target Pipeline / Monthly Quota) × Win Rate × Close Rate* = actual expected revenue. Most teams build pipeline without the friction math.

• Pavilion scouts show 4.5–5.0× coverage is table stakes (some argue 4.0× for high-velocity teams, 6.0× for complex sales)
• Clari data across 800+ teams finds that >40% of open deals never close—they just linger
• Gong call transcripts reveal reps padding pipeline with "interested" conversations, not buying signals

Velocity Check: Days-to-Close by Stage

Compare your actual average time-in-stage to your playbook.

If your Negotiation stage is 30+ days, you're holding dead deals. Force Management reps see this kill forecasts.

The MEDDPICC Reality

MEDDPICC disciplines filter noise fast:

• Metrics champion agreement (not "interested")
• Economic buyer identified (not "committee")
• Decision process in writing (not "we'll decide soon")
• Decision criteria match your solution (not vague)

Deals failing even one gate belong in lower tiers, not weighted in coverage.

How to Audit Bloat Right Now

1. Stage-exit rates — if 60% of deals in a stage never move, that stage is a graveyard
2. Stale deals (untouched >21 days) get automatic downgrade or kill
3. Champion depth — proposals with one stakeholder touchpoint in 30 days aren't real
4. Pricing alignment — if deal size has grown 3× without scope/contract amendment, it's fiction

Tools that surface this:

• Clari predictability, Gong call cadence, Bridge Group playbook benchmarks

Fat pipeline is reps hunting hard *with velocity*. Stuffed pipeline is reps hunting *everywhere* with no discipline.

TAGS: pipeline-hygiene,forecast-accuracy,deal-velocity,coverage-ratio,stage-gates,MEDDPICC,sales-ops,pipeline-bloat</answer>

Primary References

• Pavilion Executive Compensation Research: https://www.joinpavilion.com/research
• Bridge Group "Sales Development Metrics": https://www.bridgegroupinc.com/research
• OpenView Partners "PLG Index": https://openviewpartners.com/blog/category/product-led-growth/
• SaaStr Annual State-of-the-Industry survey: https://www.saastr.com/saastr-annual/
• Forrester B2B Buyer Studies: https://www.forrester.com/research/b2b/
• U.S. BLS — Sales & Related Occupations: https://www.bls.gov/ooh/sales/

Cited Benchmarks (Replace Generic %s)

The Bear Case (Capital Markets & Funding)

Three funding risks:

1. Valuation compression — public SaaS multiples ranged 4-18× in 5yrs. Future compression to 3-5× changes exit math.
2. Venture funding tightening — Series B+ harder per Carta. Longer fundraises, tougher dilution.
3. Strategic-acquisition window — large acquirer M&A appetites cyclical. 2023-2024 paused; continued pause limits exits.

Mitigation: $1.5+ ARR/$ raised, default-alive at 18mo, 2+ exit optionalities.

See Also (related library entries)

Cross-references for adjacent operator topics drawn from the current 10/10 library set, ranked by tag overlap with this entry:

• q1140 — What's the right way to handle "we need to think about it" when the buyer ghosts you for 2 weeks after?
• q1134 — What's the right way to clean up a pipeline that has 60% deals older than 90 days?
• q262 — What's the right way to measure an enablement function's actual impact on revenue versus just course-completion rates?
• q9550 — What's the right pricing-governance model for a founder-led company in a highly competitive vertical where rigid discount authority could ki
• q9543 — If your founder isn't actively selling but still wants pricing oversight, should CPQ governance shift entirely to a formal deal desk, or is
• q9520 — How do you build a tracking system for deal slippage that distinguishes between forecast inaccuracy, AE optimism, and structural process pro

Follow the q-ID links to read each in full.